explore -WSS

explore

author：leisure time 2025-10-02 23:45:42 - browse：3

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Fed up with FDA, ALS advocates consider a take

entertainment

knowledge

WSS

White House Covid adviser calls on docs to combat misinformation

WHO may add ‘noma' to its list of neglected tropical diseases

Telehealth options flood the market as retailers push virtual care

Meta's Zuckerberg and Chan on track to put $50 billion into science

What happened to the House vote on health price transparency?

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Wikipedia

explore

entertainment

At least 13 dead in Texas as scorching temps continue

Eli Lilly to pay $200M for Beam’s stake in gene

Sports medicine is finally prioritizing gender equality

Senate panel to vote on hospitals, PBMs, prisoner care

Psychedelics group wrestles with new pharma identity

First Opinion Podcast: How to protect health care in times of war

Tori Bowie and the unacceptable rates of Black maternal death

'A game

Medical records are filled with copy

Why Sanofi got shellacked over its spinoff

focus

Traditional Chinese medicine benefits explored in new JAMA study

'A game

House panel takes first step toward fixing drug shortages

Medtronic CEO on promising devices for diabetes, hypertension

Emergency medicine has repudiated 'excited delirium.' Now what?

What happened to the House vote on health price transparency?

knowledge

knowledge

explore

hotspot